Massa Silvia, Franconi Rosella, Brandi Rossella, Muller Antonio, Mett Vadim, Yusibov Vidadi, Venuti Aldo
ENEA, Italian National Agency for New Technologies, Energy and the Environment, BAS BIOTEC GEN, C.R. Casaccia, Via Anguillarese 301, 00123 Rome, Italy.
Vaccine. 2007 Apr 20;25(16):3018-21. doi: 10.1016/j.vaccine.2007.01.018. Epub 2007 Jan 19.
The E7 oncoprotein from Human Papilloma Virus (HPV) is an attractive candidate for anti-cancer vaccine development. In this study, we engineered HPV16 E7 coding sequence (wild type or mutagenized sequence, E7GGG) as fusions to beta-1,3-1,4-glucanase (LicKM) of Clostridium thermocellum and produced in Nicotiana benthamiana plants using a transient expression system. Target antigens were purified and evaluated in mice for their potential as prophylactic and therapeutic vaccine candidates. Both fusion proteins induced E7-specific IgG and cytotoxic T-cell responses and protected mice against challenge with E7-expressing tumor cells. Furthermore, when administered after challenge, these plant-produced antigens prevented tumor development.
人乳头瘤病毒(HPV)的E7癌蛋白是抗癌疫苗研发的一个有吸引力的候选物。在本研究中,我们将HPV16 E7编码序列(野生型或诱变序列,E7GGG)设计为与嗜热栖热梭菌的β-1,3-1,4-葡聚糖酶(LicKM)融合,并使用瞬时表达系统在本氏烟草植物中生产。对靶抗原进行纯化,并在小鼠中评估其作为预防性和治疗性疫苗候选物的潜力。两种融合蛋白均诱导了E7特异性IgG和细胞毒性T细胞反应,并保护小鼠免受表达E7的肿瘤细胞的攻击。此外,在攻击后给予这些植物产生的抗原可预防肿瘤发展。